| February 8, 2018 | Quiet period prior to the annual report begins (4 weeks) | |
| March 2, 2018 | Deadline for shareholder proposals for the AGM | |
| March 8, 2018 | Annual report for 2017 | |
| April 13, 2018 | Annual General Meeting | |
| April 19, 2018 | Quiet period prior to the Interim report begins (2 weeks) | |
| May 3, 2018 | Interim report - 3 months 2018 | |
| August 2, 2018 | Quiet period prior to the Interim report begins (2 weeks) | |
| August 16, 2018 | Interim report - 6 months 2018 | |
| October 25, 2018 | Quiet period prior to the Interim report begins (2 weeks) | |
| November 8, 2018 | Interim report - 9 months 2018 |
For further information, please contact:
Gry Husby Larsen, General Counsel
Peter M. Eriksen, CEO
Telephone +45 4529 0000, e-mail investor@bioporto.com
About BioPorto
BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the Nasdaq Copenhagen stock exchange.
